Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has reported E.P.S. of $-0.08 for its fourth fiscal quarter (ending December 31) versus $-0.04 for the same period a year ago. E.P.S. were $-0.33 for the latest four quarters through December 31 versus $0.04 for the same period a year ago — a decline of -925%.
Recent Price Action
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) stock closed at $4.70 on 2/13/25 after a modest decline of -1.1%. Moreover, trading volume in this decline was unusually high at 153% of normal. The stock has risen 3.8% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Vanda Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Vanda Pharmaceuticals has a good Appreciation Score of 76 but a poor Power Rating of 19, leading to the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment